4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Arbutus Biopharma Corporation (ABUS) operates in the Biotechnology industry and is headquartered in Warminster, United States with about 19 employees. Its market capitalization is roughly $865 million. In the fiscal year ended 2025-12-31, ABUS reported $14M in revenue and ($34M) in net income.
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States.
Interactive charts & full statements → Open the ABUS valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $14M | $6M | $18M | $39M | — |
| Operating Income (EBIT) | ($27M) | ($70M) | ($78M) | ($63M) | — |
| Net Income | ($34M) | ($70M) | ($73M) | ($70M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $179M | $1M | $0M | $11M | $2M |
| Operating Income (EBIT) | $169M | ($8M) | ($8M) | $2M | ($13M) |
| Net Income | $170M | ($4M) | ($8M) | $2M | ($24M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $95M | $132M | $144M | $195M | — |
| Total Liabilities | $18M | $34M | $38M | $59M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ABUS viewer.
About TickerBase · Data methodology & sources